Evaluation of the efficacy and safety of switching to tenofovir, emtricitabine, and rilpivirine in treatment-experienced patients.

Laure Surgers Nadia Valin Céline Viala Anders Boyd Laurent Fonquernie Pierre-Marie Girard Laurence Morand-Joubert Jean-Luc Meynard

J Acquir Immune Defic Syndr

*Service des Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine, Assistance Publique -Hôpitaux de Paris, Paris, France †Université Paris 6 Pierre et Marie Curie, Paris, France ‡Unité de Virologie, AP-HP, Hôpital Saint-Antoine, Paris, France §INSERM, UMR_S 1136, Institut Pierre Louis d¹Epidémiologie et de Santé Publique, Paris, France.

Published: January 2015

Download full-text PDF	Source
http://dx.doi.org/10.1097/QAI.0000000000000401	DOI Listing

Publication Analysis

Top Keywords

evaluation efficacy

efficacy safety

safety switching

switching tenofovir

tenofovir emtricitabine

emtricitabine rilpivirine

rilpivirine treatment-experienced

treatment-experienced patients

evaluation

safety

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!